Tibet Pharmaceutical: Net profit for the first half of 2026 reached 608 million yuan, a year-on-year increase of 7.16%.

Tibet Pharmaceutical Company announced that its operating revenue for the first half of 2026 was 1.554 billion yuan, a year-on-year decrease of 5.83%; the net profit attributable to shareholders of the listed company was 608 million yuan, a year-on-year increase of 7.16%; the net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 440 million yuan, a year-on-year decrease of 19.00%. The company plans to distribute a cash dividend of 1.15 yuan per share to all shareholders based on the total share capital excluding shares held in the repurchase account.